Identify The Right Patient Populations for Targeted Therapies with Highly Sensitive and Quantitative Biomarker Detection

A cutting-edge companion diagnostic platform that enhances the precision of patient stratification in clinical trials, reducing development costs and increasing the likelihood of regulatory approval.

By leveraging our patented nanotechnology and AI-powered analysis, we provide highly sensitive and quantitative biomarker detection, enabling pharmaceutical firms to identify the right patient populations for targeted therapies. Our technology accelerates drug development by offering more reliable, reproducible data and facilitating personalized treatment strategies, ultimately shortening time-to-market and optimizing the success rates of novel cancer treatments.

01

Vega BioImaging’s patented nanobeads are designed for highly sensitive and specific detection of cancer biomarkers. These color-coded beads provide quantitative and multiplexed biomarker analysis, allowing for simultaneous detection of multiple targets in a single biopsy sample. The nanobeads offer exceptional stability and reproducibility, significantly improving the accuracy of cancer subtype identification and reducing diagnostic errors in clinical trials. This technology ensures precise patient stratification, optimizing drug efficacy assessment.

02

Our advanced optical system enhances the visualization and detection of biomarkers through innovative illumination techniques. It captures high-resolution images of biopsy samples, enabling precise measurement of nanobead signals. Unlike traditional fluorescence-based systems, Vega’s optical technology avoids signal degradation, ensuring consistent and reliable results. This system is easy to integrate into clinical and research workflows, providing pharmaceutical companies with a robust tool for accurate and scalable diagnostics during drug development.

03

Vega BioImaging’s AI algorithms enable rapid, automated interpretation of complex data from biomarker tests. By analyzing patterns in biomarker expression, our platform provides actionable insights, improving diagnostic precision and reducing human error. The AI system supports pharmaceutical companies by streamlining patient selection, accelerating trial processes, maximizing trial outcomes and supporting personalized treatment approaches.

We collaborate with pharmaceutical companies to develop tailored diagnostics that accurately stratify patients for clinical trials, ensuring that therapies are tested on the most suitable populations, improving trial efficiency, and boosting success rates.

Our technology provides robust and reproducible validation of biomarkers to identify critical indicators for drug efficacy, leading to faster regulatory approval and more targeted treatments.

Through quantitative, multiplexed biomarker analysis, we assist in patient selection and monitoring, reducing trial errors, enhancing data accuracy, and accelerating timelines.

Partner with Vega BioImaging to revolutionize your drug development process. Discover how our cutting-edge diagnostics can enhance precision, reduce costs, and accelerate time-to-market.